Kala Pharmaceuticals, Inc. (KALA) |
|
8.9 0.07 (0.79%)
|
09-29 16:00 |
|
Open: |
8.79 |
Pre. Close: |
8.83 |
|
High:
|
9.0999 |
Low:
|
8.76 |
|
Volume:
|
12,292 |
Market Cap:
|
23(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:28:35 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 13.74  One year: 15.94 |
| Support: |
Support1: 8.72 Support2: 7.25 |
| Resistance: |
Resistance1: 11.76 Resistance2: 13.64 |
| Pivot: |
10.27 |
| Moving Average: |
MA(5): 9.21 MA(20): 10.69
MA(100): 14.01 MA(250): 13.47 |
| MACD: |
MACD(12,26): -1.1 Signal(9): -1 |
| Stochastic oscillator: |
%K(14,3): 4.7  %D(3): 3.3 |
| RSI: |
RSI(14): 18.6 |
| 52-week: |
High: 56.72 Low: 3.54 |
| Average Vol(K): |
3-Month: 34 (K) 10-Days: 20 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KALA ] has closed above bottom band by 8.8%. Bollinger Bands are 28.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
9.12 - 9.18 |
9.18 - 9.24 |
|
Low:
|
8.61 - 8.69 |
8.69 - 8.76 |
|
Close:
|
8.78 - 8.9 |
8.9 - 9.01 |
|
Company Description |
|
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts. |
Headline News |
Thu, 21 Sep 2023
Ocular Drug Delivery Global Market Leading Global Companies and Regional Average Pricing Analysis By 2027 | Pf - openPR
Tue, 19 Sep 2023
High Prevalence of Autoimmune Diseases and Favorable ... - GlobeNewswire
Thu, 07 Sep 2023
Ocular allergies and dry eye disease: Overlapping treatment options - Optometry Times
Tue, 05 Sep 2023
KALA BIO to Present at H.C. Wainwright 25th Annual Global ... - Marketscreener.com
Wed, 02 Aug 2023
Kala Pharmaceuticals Announces Name Change to KALA BIO - Yahoo Finance
Wed, 19 Jul 2023
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
0 (M) |
| Shares Float |
3 (M) |
|
% Held by Insiders
|
1.97e+006 (%) |
|
% Held by Institutions
|
33 (%) |
|
Shares Short
|
93 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.261e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-10 |
|
Return on Assets (ttm)
|
235.9 |
|
Return on Equity (ttm)
|
-35.5 |
|
Qtrly Rev. Growth
|
420000 |
|
Gross Profit (p.s.)
|
0.56 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-47 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.94 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
9210 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
